Eva Ciruelos

19.2k total citations · 7 hit papers
208 papers, 7.1k citations indexed

About

Eva Ciruelos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eva Ciruelos has authored 208 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Oncology, 118 papers in Pulmonary and Respiratory Medicine and 79 papers in Cancer Research. Recurrent topics in Eva Ciruelos's work include HER2/EGFR in Cancer Research (104 papers), Advanced Breast Cancer Therapies (100 papers) and Cancer Treatment and Pharmacology (91 papers). Eva Ciruelos is often cited by papers focused on HER2/EGFR in Cancer Research (104 papers), Advanced Breast Cancer Therapies (100 papers) and Cancer Treatment and Pharmacology (91 papers). Eva Ciruelos collaborates with scholars based in Spain, United States and Italy. Eva Ciruelos's co-authors include Javier Cortés, Mario Campone, José Baselga, Andreas Schneeweiß, Sung‐Bae Kim, Jungsil Ro, Emma Clark, Sandra M. Swain, Mark Benyunes and Jean-­Marc Ferrero and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Eva Ciruelos

201 papers receiving 7.0k citations

Hit Papers

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive M... 2010 2026 2015 2020 2015 2010 2013 2020 2023 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    2015 1.4k citations Sandra M. Swain, José Baselga et al. profile →
  2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
    2010 891 citations Luca Gianni, Semiglazov Vf et al. profile →
  3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    2013 700 citations Sandra M. Swain, Sung‐Bae Kim et al. The Lancet Oncology profile →
  4. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
    2020 371 citations Eva Ciruelos, Mario Campone et al. Annals of Oncology profile →
  5. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
    2023 210 citations Hope S. Rugo, Aditya Bardia et al. profile →
  6. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
    2022 204 citations Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology profile →
  7. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2022 176 citations Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Ciruelos Spain 32 5.3k 2.4k 2.3k 1.5k 1.5k 208 7.1k
Arlene Chan Australia 30 5.4k 1.0× 1.7k 0.7× 2.3k 1.0× 1.8k 1.1× 1.1k 0.8× 144 6.8k
Emma Clark United Kingdom 20 5.1k 1.0× 1.6k 0.7× 1.7k 0.7× 1.2k 0.8× 2.1k 1.4× 50 6.2k
Beth Overmoyer United States 33 4.4k 0.8× 1.9k 0.8× 1.3k 0.5× 1.5k 1.0× 884 0.6× 143 6.2k
Joyce O’Shaughnessy United States 40 7.0k 1.3× 3.1k 1.3× 2.8k 1.2× 2.1k 1.4× 739 0.5× 240 9.6k
Jean-­Marc Ferrero France 41 6.4k 1.2× 3.0k 1.2× 4.0k 1.7× 1.8k 1.2× 2.0k 1.4× 207 9.6k
Roberto Hegg Brazil 25 6.6k 1.3× 2.4k 1.0× 2.3k 1.0× 1.5k 1.0× 1.6k 1.1× 87 8.3k
Graham Ross United Kingdom 22 8.1k 1.5× 2.2k 0.9× 2.2k 0.9× 2.3k 1.5× 2.9k 1.9× 42 9.3k
Gilles Romieu France 37 4.8k 0.9× 1.9k 0.8× 2.1k 0.9× 1.2k 0.8× 873 0.6× 136 6.2k
María Koehler United States 26 5.0k 0.9× 1.9k 0.8× 3.4k 1.5× 1.5k 1.0× 925 0.6× 112 7.0k
Erika Hamilton United States 42 6.0k 1.1× 1.3k 0.5× 2.8k 1.2× 1.9k 1.2× 1.5k 1.0× 432 8.1k

Countries citing papers authored by Eva Ciruelos

Since Specialization
Citations

This map shows the geographic impact of Eva Ciruelos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Ciruelos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Ciruelos more than expected).

Fields of papers citing papers by Eva Ciruelos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Ciruelos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Ciruelos. The network helps show where Eva Ciruelos may publish in the future.

Co-authorship network of co-authors of Eva Ciruelos

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Ciruelos. A scholar is included among the top collaborators of Eva Ciruelos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Ciruelos. Eva Ciruelos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oliveira, Mafalda, Eva Ciruelos, Guillermo Villacampa, et al.. (2025). Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial. Clinical Cancer Research. 32(3). 468–478.
2.
Bardia, Aditya, Lajos Pusztai, Kathy S. Albain, et al.. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology. 16. 12693072–12693072. 16 indexed citations
3.
Villacampa, Guillermo, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2024). Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B). ESMO Open. 9(3). 102388–102388. 7 indexed citations
4.
Tolaney, Sara M., Nadine Tung, Antonio C. Wolff, et al.. (2024). HER2DX genomic test in early-stage HER2-positive breast cancer. ESMO Open. 9(12). 103987–103987. 8 indexed citations
5.
Pascual, Tomás, Juan Miguel Cejalvo, Mafalda Oliveira, et al.. (2023). 387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer. Annals of Oncology. 34. S341–S342. 1 indexed citations
6.
7.
Ayala, Francisco, Silvia Antolín, Joaquín Gavilá Gregori, et al.. (2023). SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). Clinical & Translational Oncology. 25(9). 2647–2664. 14 indexed citations
8.
Gianni, Luca, Chiun‐Sheng Huang, Daniel Egle, et al.. (2022). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Annals of Oncology. 33(5). 534–543. 204 indexed citations breakdown →
9.
Rugo, Hope S., Aditya Bardia, Frederik Marmé, et al.. (2022). Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 40(29). 3365–3376. 176 indexed citations breakdown →
10.
Carretero-González, Alberto, Marta Hergueta‐Redondo, Sara Sánchez‐Redondo, et al.. (2022). Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis. OncoImmunology. 11(1). 2067944–2067944. 19 indexed citations
11.
Villacampa, Guillermo, Claudette Falato, Laia Paré, et al.. (2022). Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. European Journal of Cancer. 174. 232–242. 4 indexed citations
12.
Shi, Zhen, Julia Wulfkuhle, Małgorzata Nowicka, et al.. (2021). Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clinical Cancer Research. 28(5). 993–1003. 31 indexed citations
13.
Martín, Miguel, José Á. García-Sáenz, Luís Manso, et al.. (2020). Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer. Future Oncology. 16(33). 2763–2778. 12 indexed citations
14.
Prat, Aleix, Yi‐Hsuan Tsai, Tomás Pascual, et al.. (2020). A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer. Clinical Cancer Research. 26(23). 6141–6148. 5 indexed citations
15.
Schettini, Francesco, Navid Sobhani, Tiziana Triulzi, et al.. (2020). Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment. 184(2). 421–431. 12 indexed citations
16.
Ciruelos, Eva, Dolores Isla, Rafael López‐López, et al.. (2019). Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. European Journal of Cancer Care. 28(6). e13164–e13164. 19 indexed citations
17.
Ayala, Francisco, Raquel Andrés, José Á. García-Sáenz, et al.. (2018). SEOM clinical guidelines in early stage breast cancer (2018). Clinical & Translational Oncology. 21(1). 18–30. 47 indexed citations
18.
Gámez‐Pozo, Angelo, Jorge M. Arevalillo, Paolo Nanni, et al.. (2015). Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications. Cancer Research. 75(11). 2243–2253. 39 indexed citations
19.
Salvador, J., Luís Manso, Juan de la Haba-Rodríguez, et al.. (2014). Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clinical & Translational Oncology. 17(2). 160–166. 10 indexed citations
20.
Swain, Sandra M., Sung‐Bae Kim, Javier Cortés, et al.. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 14(6). 461–471. 700 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arlene Chan Breakdown of academic impact, for papers by Emma Clark Breakdown of academic impact, for papers by Beth Overmoyer Breakdown of academic impact, for papers by Joyce O’Shaughnessy Breakdown of academic impact, for papers by Jean-­Marc Ferrero Breakdown of academic impact, for papers by Roberto Hegg Breakdown of academic impact, for papers by Graham Ross Breakdown of academic impact, for papers by Gilles Romieu Breakdown of academic impact, for papers by María Koehler Breakdown of academic impact, for papers by Erika Hamilton
Rankless by CCL
2026